2021-2022 Legislative Session

#### **Fiscal Note**

#### HF648 - 1A - Health Plans Prohibited from Limiting Opioid Tests

Chief Author: Erin Koegel

Commitee: State Government Finance and Policy

Date Completed:

Agency: Minn Management and Budget

State Fiscal Impact	Yes	No
Expenditures		Х
Fee/Departmental Earnings		Х
Tax Revenue		Х
Information Technology		Х
Local Fiscal Impact		X

This table shows direct impact to state government only. Local government impact, if any, is discussed in the narrative. Reductions shown in the parentheses.

State Cost (Savings)		Biennium		Biennium	
Dollars in Thousands	FY2021	FY2022	FY2023	FY2024	FY2025
Tota	-	-	-	-	-
В	iennial Total		-		-

Full Time Equivalent Positions (FTE)		Biennium		Biennium	
	FY2021	FY2022	FY2023	FY2024	FY2025
To	otal -	-	-	-	-

### **LBO Analyst's Comment**

I have reviewed this fiscal note for reasonableness of content and consistency with the LBO's Uniform Standards and Procedures.

 LBO Signature:
 Joe Harney
 Date:
 3/3/2021 3:10:53 PM

 Phone:
 651-284-6438
 Email:
 joe.harney@lbo.leg.mn

# **Preliminary**

#### State Cost (Savings) Calculation Details

This table shows direct impact to state government only. Local government impact, if any, is discussed in the narrative. Reductions are shown in parentheses.

<sup>\*</sup>Transfers In/Out and Absorbed Costs are only displayed when reported.

State Cost (Savings) = 1-2	st (Savings) = 1-2		Biennium		Biennium	
Dollars in Thousands		FY2021	FY2022	FY2023	FY2024	FY2025
	Total	-	-	-	-	-
	Bier	nial Total		-		-
1 - Expenditures, Absorbed Costs*, Tran	sfers Out*					
	Total	-	-	-	-	-
	Bier	nial Total		-		-
2 - Revenues, Transfers In*						
	Total	-	-	-	-	-
	Bier	nial Total		-		-

#### **Bill Description**

This bill prohibits health plans from placing annual or lifetime limits on screenings and urinalysis testing for opioids for members in an inpatient or outpatient substance use disorder treatment program, when ordered by a health care provider and performed by an accredited clinical laboratory. A health plan administrator may conduct medical necessity review when screenings or urinalysis testing for a member exceeds 24 tests within a 12-month period.

#### **Assumptions**

Minnesota Management and Budget (MMB) administers the State Employee Group Insurance Program (SEGIP) which provides health, dental, life and other benefits to eligible State employees and their dependents, and other groups including quasi-state agencies under the legislative authority provided in Minnesota Statutes 43A. Health benefits are provided through the self-funded Minnesota Advantage Health Plan. SEGIP contracts with three health plan administrators to administer medical benefits and a Pharmacy Benefit Manager (PBM) to administer its prescription drug benefit.

SEGIP has made several assumptions while assessing the potential fiscal impact of this bill:

- · Utilization patterns of screening and urinalysis testing for opioids will remain the same among SEGIP's membership.
- The language of this bill implies medical necessity for the screening and urinalysis testing.
- The language of this bill does not cover full drug panels or daily urinalysis testing just because opioids are a component of those tests.

SEGIP does not expect a fiscal impact from this legislation. Under the Minnesota Advantage Plan, SEGIP's health plan administrators do not limit screenings or urinalysis testing for opioids when those procedures are performed at in-network laboratories.

# **Expenditure and/or Revenue Formula**

#### **Long-Term Fiscal Considerations**

## **Local Fiscal Impact**

#### References/Sources

# Preliminary

Program Information and claims data from SEGIP, administered by MMB.

Agency Contact: Lorna Smith, 651-259-3604

**Agency Fiscal Note Coordinator Signature:** Paul Moore **Date:** 3/3/2021 1:13:47 PM

Phone: 651-201-8004 Email: paul.b.moore@state.mn.us